Clinical Trials
21 trialsNCT06915246 2026-03-27
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
VIVUS LLC
Phase 2 Recruiting
NCT04871607 2025-12-04
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT03125642 2025-11-04
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT01141712 2023-01-04
Autologous Transplant in HIV Patients (BMT CTN 0803)
Medical College of Wisconsin
Phase 2 Completed
NCT00345865 2020-07-14
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01008462 2019-06-11
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00002461 2018-08-17
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
Montefiore Medical Center
Phase 2 Completed
NCT00233987 2018-03-01
S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT01969435 2018-02-13
Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT00005985 2017-11-29
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00005998 2017-11-29
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT00281879 2017-09-27
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00691015 2017-06-28
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00388349 2017-06-14
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Stanford University
Phase 2 Completed
NCT01220297 2017-06-05
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Stanford University
Phase 2 Terminated
NCT00003631 2016-01-25
Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01500161 2013-11-25
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Texas Oncology Cancer Center
Phase 2 Terminated
NCT00908180 2013-08-02
Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005613 2013-06-04
CBV
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00060255 2013-05-09
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
Roswell Park Cancer Institute
Phase 2 Completed
NCT00002552 2013-04-09
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed